DIAGNOS Provides Update on Business Operations
Momentum Public Relations
Press Release: July 31 2018
Diagnos Inc.(ADK:V) (DGNOF:OTCQB), a leader in early detection of critical health issues through the use of Artificial Intelligence (AI), announces today an update on business operations.
We are happy to report these important milestones and accomplishments over the last twelve months:
- Signing of our first agreement with a Canadian hospital, the CHUM in Montreal. This hospital is now screening patients for diabetic retinopathy and hypertension. We expect to screen 4,500 patients from August to December of 2018. It is estimated that the diabetic population in Quebec is 800,000,
- Signing of a 3-year contract with our first customer in the USA after a successful pilot. We are currently screening an average of 600 patients per month and our customer is ordering additional cameras,
- First contract in Saudi Arabia with a local partner. We began with 100 patients screened per month and now we are averaging 1,000 per month,
- Working with pharmaceutical companies such as Novo Nordisk to broaden the use of our AI technology for the detection of Hypertension complications in the retina of the eye,
- Opening of our first of 15 clinics in Panama and a new provincial government state in Mexico. We have several new proposals in Latin America with many governments and clinics.
- Establishing a sales force to cover Latin America and the USA including existing international accounts. The Mexican government has temporarily stopped the mass screening program because of elections in Mexico. Now that the election results are known, we plan to restart the program soon.
CARDIO, our new Hypertension application announced recently, is a by-product of the work we are doing in the field of stroke prevention based on the analysis of the human vascular system. This new prevention tool is in clinical trial in the US, Canada, Algeria and Mexico. We are working with other hospitals and we expect to see more organisations collaborating with DIAGNOS in the development of CARDIO.
The Corporation is working at establishing a permanent team to cover the US market. The addition of a new US based board member, Dr. Reid Maclellan, is contributing to the business development efforts there. Dr. Maclellan, an Instructor of Surgery in the field of vascular anomalies at Harvard Medical School, will contribute to DIAGNOS’ growth in the US. Additionally we made changes at the board level in bringing new senior talent to improve corporate governance.
“The last year was a pivotal period for DIAGNOS. The AI market came alive in 2017. We believe this demonstrates that all the work done by our employees to become an early leader is finally benefiting the Corporation. For the last 2 years, DIAGNOS has been working with clients in 16 countries to establish a local presence and this proves that the use of AI in the medical field is really happening. In our opinion, the learning curve for any high tech company to be fully able to access the medical market is at least 5 years. We also strongly believe we’ve got the right timing with our AI solutions. Regulatory approvals such as FDA, Health Canada, CE mark, COFEPRIS plus others and the proof of concept have been successfully achieved at DIAGNOS,’’ said André Larente, President and CEO of DIAGNOS.
About DIAGNOS
DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele- ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (“POC”). CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time and has been cleared for commercialization by several regulatory authorities such as Health Canada, the U.S. Food and Drug Administration and the European Union.
Additional information about DIAGNOS is available at www.diagnos.com and www.sedar.com.
For further information, please contact:
André Larente, President | Josh Falle |
DIAGNOS Inc. | Momentum PR |
Tel: 450-678-8882 ext. 224 | Tel: 514-416-4656 |
alarente@diagnos.ca | josh@momentumpr.com |
This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publically update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- Published in Diagnos
ARCTIC STAR REPORTS SPRING EXPLORATION PROGRAM RESULTS FROM DIAGRAS PROPERTY, NORTHWEST TERRITORIES, CANADA
Momentum Public Relations
Press Release: July 31 2018
Arctic Star Exploration Corp.(ADD:V) has provided an update on the outcome of its 2018 spring exploration program on its Diagras property (located in the Northwest Territories, Canada). Diagras is a contributing joint venture between Arctic Star, which holds a 40-per-cent interest, and Margaret Lake Diamonds Inc., which holds a 60-per-cent interest, and acts as project operator.
Diagras property
Exploration at Diagras consisted of gravity, magnetic and electromagnetic (EM) ground surveys focused around historically identified kimberlites as well as other airborne geophysical anomalies with kimberlite-like signatures. This groundwork is designed to develop targets for a spring 2019 drill program.
Diagras is located in the prolific Lac de Gras diamond field just 35 kilometres from the world-class Diavik diamond mine. The property lies directly on trend with the Diavik deposits currently being mined by a joint venture between Rio Tinto and Dominion Diamond Diavik. The Diagras land package consists of 18,699 contiguous hectares of mineral claims containing 12 previously identified kimberlites.
Fieldwork was completed by Aurora Geosciences Ltd. (AGL) and Initial Exploration Services Inc. (IES) between May 27 and June 6, 2018. The surveys targeted kimberlite intrusions and were designed to investigate areas proximal to known kimberlites as well as explore new target areas. Warm temperatures during the time of the surveys caused a rapid snowmelt and flooding of the ice-covered lakes. The conditions forced a premature end to the program leaving some of the planned target areas untested. This work is planned to be completed in 2019.
A total of 133 gravity stations, 152 line kilometres of magnetics and 11.2 line kilometres of OhmMapper survey were completed.
Drill targets identified
Of the surveys conducted this year, DG007, HL02 and Suzanne have emerged as interesting, drillable targets, showing evidence of multiphase kimberlite complexes.
At Suzanne, a combined EM and gravity anomaly distinctly breaks a diabase dike, with a separate magnetic low to the south. The company has not located the previous drill holes, but it is likely they targeted either the EM or the magnetic anomaly, but not both. The anomaly is large enough (250 m) to deserve more than one drill hole to search for different phases.
At HL02, two long-angle holes from the shoreline (the anomaly is in a lake) were targeted and completed within this kimberlite by the previous explorers. The magnetic signature in this area is complex, suggesting the possibility of untested phases. The partly completed EM survey conducted this year shows an EM anomaly associated with the kimberlite but not tested directly by previous drilling.
At the DG007 anomaly, previous explorers targeted a classic Lac de Gras, magnetic and EM anomaly. Two holes were drilled but failed to explain this anomaly, intersecting only granite. One of the drill collars has been found in the field and its position is displaced from that reported in assessment files, possibly due to GPS (global positioning system) errors. Drilling to properly explain this target, which the company believes is likely to be kimberlite, is required.
The joint venture was also successful using this strategy during the spring 2017 exploration program. This work revealed gravity and EM anomalies proximal to known magnetic kimberlites that constitute compelling drill targets. At the Jack Pine kimberlite, which is one of the largest kimberlite complexes in the Lac de Gras diamond field (over 1.5 km in its longest dimension), the geophysical methods (ground gravity, EM and magnetics) highlighted obvious magnetic kimberlite phases drilled by previous explorer De Beers Canada while also successfully defining a new kimberlite-like geophysical expression, in the form of coincident gravity and EM anomalies. At the Black Spruce kimberlite, a series of gravity lows occur adjacent to the south of the known magnetic phase of the kimberlite. One of these gravity anomalies clearly breaks and disturbs a diabase dike, a common characteristic of many Lac de Gras kimberlites.
The company now has drill targets with high potential to discover new kimberlite or untested kimberlite phases in one of the best diamond addresses in the world, close to the operating Ekati and Diavik diamond mines.
Future plans Diagras project
The company plans to drill test the referenced targets as well as generate more targets through an expanded ground geophysical and drill program in spring 2019.
Qualified person
The qualified person for this news release is Buddy Doyle, AUSIMM, a geologist of over 30 years experience in diamond exploration, discovery and evaluation.
About Arctic Star Exploration Corp.
The company owns 100 per cent of the recently acquired Timantti diamond project, including a 243-hectare exploration permit and a 193,700-hectare exploration reservation near the town of Kuusamo, in Finland. The project is located approximately 550 kilometres southwest of the operating Grib diamond mine in Russia. Arctic has commenced its exploration in Finland on the Timantti project, where four diamondiferous kimberlite bodies may represent the first finds in a large kimberlite field. The company also controls diamond exploration properties in Nunavut (Stein), the Northwest Territories (Diagras and Redemption) and a rare metals project in British Columbia (Cap).
We seek Safe Harbor.
- Published in Arctic Star Exploration
Tetra Natural Health Announces Upcoming Launch of Hemp Energy Drink
Momentum Public Relations
Press Release: July 19 2018
Tetra Natural Health Inc., a division of Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP) (OTCQB:TBPMF), announced that it will be commercializing Hemp Energy Drink, a caffeinated energy drink containing hemp, that received a Temporary Marketing Authorization (TMA) by Health Canada. Tetra intends on launching this product ahead of the upcoming legalization as it begins to position itself as a player in the natural health product market.
Hemp Energy Drink is developed for those who want to have a clear and focused mind and live an active and fun lifestyle. It can be consumed whenever people are in need of energy whilst working, driving or playing sports and leisure activities. The functional benefits of hemp energy drink are mainly to help for concentration, alertness and to contribute to mental performance and reduction of fatigue.
Hemp Energy Drinks are already available in the U.S.A. and in several European countries, and the European Food Safety Authority confirmed the positive health effects related to the ingredients of Hemp Energy Drink.
Tetra Natural Health has a team of natural health experts that have been preparing to commercialize products containing hemp or that act on the cannabinoid receptors under the existing Food and Drug regulations. To lead and support the team, Tetra recently announced the arrival of Richard Giguere, Executive Vice President Commercial Operations who will implement and oversee the natural health product commercial sales and growth strategy.
Richard has more than 20 years’ experience in sales and marketing including OTC, natural products and original pharmaceutical medications. His arrival was perfectly aligned with Tetra Natural Health’s goal to develop and sell hemp, cannabis and cannabinoid-based OTC (self-care) products to leverage the post-legalization market. Tetra obtained the rights to the TMA and plans on expanding this food product line as part of a structured sales driven growth plan.
About Tetra Natural Health:
Tetra Natural Health Inc. is a subsidiary of Tetra Bio-Pharma Inc, (TSX-V: TBP) (OTCQB: TBPMF) that is focusing on retail commercialization of hemp, cannabis or cannabinoid-based products authorized by Health Canada for sale.
Tetra Bio-Pharma is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of its mission, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
For further information, please contact Tetra Natural Health Inc.:
Richard Giguere, Executive Vice President, Commercial Operations
richard.giguere@tetrabiopharma.com
438 899-7575 ext 210
For media information, please contact:
Daniel Granger
Daniel.granger@acjcommunication.com
ACJ Communication
O: 1 514 840 7990
M: 1 514 232 1556
- Published in Tetra Bio Pharma
Relevium’s Biocannabix Receives City Approval for Medical Cannabis Facility
Momentum Public Relations
Press Release: July 19 2018
Relevium TechnologiesInc. (TSX.V:RLV) (OTCQB:RLLVF) and (Frankfurt:6BX) (the “Company” or “Relevium”), is pleased to announce that the company’s wholly owned subsidiary Biocannabix Health Corporation (“BCX”) has received an approval letter from the City of Ville St-Laurent (VSL), located in Montréal, Québec for the Company’s 93,000 SQ. FT. cultivation and fully integrated processing facility under the Access to Cannabis for Medical Purposes Regulations (ACMPR).
Aurelio Useche, CEO of Relevium stated: “The approval letter from the City of Ville Saint-Laurent constitutes an important milestone for the Company as it provides the project with municipal support and considerably de-risks the process.” Mr. Useche continued: “To our knowledge the Biocannabix facility will be the most central ACMPR licensed producer in the Greater Montreal area, a city that is the second largest population center in Canada and with its strategic location, which is situated 20 minutes from the downtown core and adjacent to the TransCanada highway. This will provide the company with an important competitive advantage.”
Now that the approval letter from the city of Saint-Laurent has been granted, the Company will now focus on finalizing the lease agreement for the facility. The Company intends to have the lease agreement finalized within the next 30 days. The Company will continue to work with its consultants, PipeDreemz Inc. on the construction design, business plan and cultivation parameters for the facility and expects to provide an update on progress by late summer.
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or brands with a focus on e-commerce in the growing health and wellness sector. The Company, through its wholly-owned subsidiary, Biocannabix Health Corporation, is also incorporating cannabinoids into its nutraceutical strategy and provide its retail customers access to the health benefits of cannabis through its formulations and established brands.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will be able to apply for and ultimately obtain an ACMPR licence, the proposed business of Biocannabix will develop as anticipated, that the Company will raise sufficient funds to develop the Biocannabix business, and that the Company will obtain all requisite regulatory approvals. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed business developments may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche
President and CEO
For more information about this press release:
Tel: +1.888.528.8687
RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com
Like us on Facebook
Follow us on Twitter
Follow us on LinkedIn
- Published in Relevium Technologies
Sirona Biochem Announces CFDA Approval of SGLT2 Inhibitor for Phase I Clinical Trial
Momentum Public Relations
Press Release: July 12 2018
Sirona Biochem Corp. (TSX-V:SBM) (FSE:ZSB) (the “Company”) announced today that partner, Jiangsu Wanbang Biopharmaceuticals (“Wanbang”), has confirmed the Investigational New Drug (IND) submission to China’s Food and Drug Administration (CFDA) for its SGLT2 inhibitor was approved for clinical trial. Wanbang will be entering a Phase I clinical trial for the treatment of Type 2 diabetes. The CFDA approval triggers a $500,000 USD milestone payment to Sirona Biochem.
Sirona Biochem’s SGLT2 inhibitor, TFC-039, was licensed to Wanbang’s parent company, Shanghai Fosun Pharmaceuticals in 2014 with rights for China. Since the initial licensing agreement, Fosun Pharma has invested more than RMB 29 million toward the development of the SGLT2 inhibitor.
According to the International Diabetes Federation and the World Health Organization, China now has some of the highest rates of diabetes cases, affecting 110 million people, or 11% of the population. Over 90% of the cases are Type 2 diabetes.
“Wanbang has been very dedicated to this project and we are pleased to be advancing to the clinic with the compound,” said Dr. Howard Verrico, CEO. “With the surging rates of diabetes in China, there remains a need for new therapies. TFC-039 will be able to enter this market as a once-daily drug or add-on therapy for the many people struggling with this disease.”
About Jiangsu Wanbang Biopharmaceuticals
Jiangsu Wanbang Pharmaceuticals manufactures and sells a variety of products including those for chronic disease treatment, antibiotics, and other endocrine diseases. Parent company, Fosun Pharma, is a leader in the pharmaceutical industry and regarded as one of the top five domestic pharmaceutical companies in China.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, please contact:
Christopher Hopton, CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
———————————————
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
- Published in Sirona Biochem
Robots Predicted to be Performing 85% of surgeries by 2025
Momentum Public Relations
Blog: July 11, 2018
AI Medical Diagnosis APP Gets Better Exam Mark Than Doctors
Exploding AI Medical Market Predicted to Hit US$12.15 Billion by 2023
Robots Predicted to be Performing 85% of surgeries by 2025
On June 28, 2018, Forbes ran a story with the headline reading, “This AI Just Beat Human Doctors on a Clinical Exam MD.”
The story by Parmy Olson, tells how an artificial intelligence application created by Babylon Health scored on a standard British test designed to grade the diagnostic ability of doctors in training. For the last five years the average passing grade has been 72%. Babylon Health’s artificial intelligence powered software performed ten points above the average coming in at 82%.
At the beginning of 2018 Research House Frost & Sullivan made some predictions. The one that perhaps best defines future shock is that by 2025, 85% of surgical procedures are likely to be done by robots. Over the next two to three years Frost & Sullivan also predict that AI platforms in medical imaging will increase productivity by 10-15%.
Babylon Health was founded five years ago and has raised US$85 million for research and development. Babylon has developed an intriguing mix of AI and human diagnosis that could if adopted drive down overall health care costs by using its diagnostic apps to pre-screen patients and suggest what’s wrong, while leaving the final diagnosis in the hands of a living breathing MD.
While at first this may seem like an episode of Star Trek, the service is real enough. The company’s largest and most important client to date is the British National Health Service which has allowed 26 thousand patients to transfer from the standard GP based service to Babylon. Another 20,000 are on a waiting list.
In a typical scenario a Babylon patient will describe symptoms to a diagnostic engine which will then suggest a probable diagnosis. Then there is the video call between doctor and patient. While the interview is going on the app automatically records and transcribes the interview. The patients face is analyzed to determine if he or she is feeling confused, worried or normal, according to the movements of 117 muscles located in the nose, lips or eyebrows. At the end of the consultation the live doctor will, if necessary send a prescription to the patients pharmacy.
The software also creates a digital twin of the patient and the company believes the twin will be used to determine what medical problems will develop in the future. All of this should help make healthcare timelier and more affordable.
Babylon’s business model is to sell its services to health care providers such as government Medicare systems or health insurance companies. The company also sells its consulting service to individuals and offers access to software that individuals can use to investigate an ailment. Babylon intends to launch in the US, during 2019.
Forbes sums up recent market activity like this, “Investment in the AI medical market is pouring in, from tech giants like IBM’s Watson, Alphabet and Philips to pharmaceutical companies and swiftly proliferating start-ups. The market for artificial intelligence in health care and the life sciences is projected to grow by 40 percent a year, to $6.6 billion in 2021, according to estimates from Frost & Sullivan.”
In March of this year research house Mordor Intelligence predicted that by 2023 the global artificial intelligence in medicine market would reach US$ 12.15 Billion. The report, Artificial Intelligence in Medicine Market-by Application and Geography-Growth, Trends, and forecasts (2018-2023) details how AI is moving into the medical workplace providing faster and more efficient medical care.
While AI can be used to manage patient records and other types of data the real payoff for AI in medical applications comes in reducing human error. When AI systems have been used in image labelling, error rates have been reduced from 28.5% to 2.5%.
According to Mordor, the artificial intelligence in medicine market will grow from US$1.6 billion in 2017 to US$12.5 billion by 2023, a CAGR of 40.15% from 2018 to 2023. A number of factors are driving the market and can be divided into two categories. On the one hand there is the increased efficiency which AI systems offer providing a more efficient diagnosis. This also applies to patient data management. Both of these, better diagnosis and better data management, will help drive down the cost of medical treatment.
The flip side of the coin is the high cost of error. According to the Mordor report preventable medical mistakes result in roughly 210,000 deaths per year. Diagnostic mistakes account for roughly 440,000 deaths per year. And finally, medical mistakes cost the healthcare industry approximately US$1 trillion per year.
As well as the companies listed above other key players developing artificial intelligence and deep learning medical applications include: Intel; Microsoft, Siemens and General Electric.
With a market value that is growing at 40% CAGR a year, the AI in medical applications market is a developing sector that retail investors should take a good look at. It is a market driven by demographic factors, as the baby boomers continue to age they will require more medical attention, and efficiency. Any technology that cuts medical costs will be highly valued.
While there are no sure bets in the stock market, one AI diagnosis company that you should take a look at is the Montreal-based Diagnos. Diagnos has specialized in developing a proprietary technology, CARA, computer assisted retinal analysis that uses enhanced retinal digital images to detect the initial stages of diabetic retinopathy.
The retina is at the back of the eye and it is the only place where doctors can observe veins and arteries and detect early diabetes. Diabetes can lead to blindness if untreated and early detection can prevent 85-90% of vision loss. The process is simple. An image of the eye is taken and then image can then be analyzed.
CARA has been used to diagnose 222,034 patients at last count, in 16 countries, using 131 screening sites. In early June, The Montreal Gazette ran a story on Diagnos’ setting up its first Canadian pilot project at the Centre hospitalier de l’Universite de Montreal (CHUM). Diagnos is a company on the move and with its shares, (TSXV: ADK) closing at $0.06 on July 10, 2018, an attractive entry point into the explosive AI medical market.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
FULL DISCLOSURE: Diagnos is a paid client of Momentum PR.
- Published in Blog
Auxico Announces Sampling Results From Colombia and Venezuela
Momentum Public Relations
Press Release: July 10 2018
Auxico Resources Canada Inc. (CSE:AUAG) is pleased to announce that it has entered into eight option agreements to acquire a 70% interest in the profits from the production of precious metals, base metals and coltan, originating from properties in Colombia and Venezuela.
The Company is pleased to report the following sampling results, which were analyzed for their metal content at the Centre de Technologie Minérale et de Plasturgie in Thetford Mines (Quebec):
Sample | % Ta | % Nb | g/t Sc | % Sn | % TiO2 |
V – M-8355_1 | 7.97 | 2.36 | 3,200 | 72.08 | 4.54 |
C – M-8355_2 | 1.03 | 3.78 | / | / | 49.02 |
C – M-8355_12 | 35.66 | 7.57 | 6,200 | 8.29 | 23.93 |
V – M-8355_234 | 26.66 | 7.70 | 4,200 | 5.35 | 23.32 |
C – M-8246_7 | 35.15 | 39.63 | / | / | 3.92 |
C – M-8246_8 | 31.14 | 36.99 | / | / | 3.33 |
The Company has also received copper/silver results for one of the option properties, as follows:
C – M-8246_1 | C – M-8246_2 | C – M-8246_4 | C – M-8246_6 | |
% Cu | 2.41 | 8.68 | 62.62 | 68.84 |
g/t Ag | / | / | 600 | 500 |
The Company is currently conducting the metallurgical testing that targets the selective extraction of tantalum, niobium, scandium and copper on selected samples using the Ultrasound Assisted Extraction (UAEx) process.
Coltan is a metallic mineral composed of niobium and tantalite, which is refined to produce tantalum. Tantalite ore currently sells for US$186 per kg. Niobium currently sells for approximately US$50 per kg. Tantalum from coltan is used to manufacture batteries for electric cars, as well as almost every kind of electronic device, including cell phones and computers. Niobium is used in superconducting alloys. Scandium oxide sells for US$4,000 per kg. Added to various aluminum alloys, scandium has high-value commercial uses, especially in the automotive and aerospace industries. Tin presently sells for US$19 per kg, and the selling price of titanium dioxide ranges from US$1,700 per metric tonne to US$2,700 per metric tonne, depending on its quality and the application.
Auxico is currently preparing to establish detailed grids over the properties for extensive sampling using augers. The program will be supervised by Auxico’s Qualified Person and will commence shortly. All of the samples will be sent to Quebec for metallurgical analysis, as well as to an accredited lab in Colombia.
Engagement of Buffalo Associates Limited
Auxico is also pleased to announce that it has engaged the services of Buffalo Associates Limited (“Buffalo Associates”). Buffalo Associates will advise Auxico on matters relating to European strategic partners and investors. Marc Bamber, the CEO of Buffalo Associates, has extensive experience in the financial industry of London, including the financing of mining companies.
Qualified Person
This news release was reviewed and approved by Joel Scodnick, P.Geo., an independent consultant to Auxico, in his capacity as a Qualified Person, as defined by National Instrument 43-101.
Disclaimer: The samples described above were all selected by the property owner. These samples were shipped to a laboratory in Quebec selected by Auxico. It is the opinion of the Qualified Person that an independent grid sampling program be established with proper control and chain of custody, and therefore the values presented above are not in compliance with NI 43-101. Because the chain of custody cannot be independently established from the above samples, the Company cautions the reader as to the reliability of the samples and the results thereof. The Company and the Qualified Person do not take any responsibility for the values presented in this news release. The results presented above are being referred to for general information purposes only, and to demonstrate the potential that these properties hold.
ON BEHALF OF THE BOARD OF DIRECTORS
« signed » | « signed » |
Pierre Gauthier | Mark Billings |
CEO, Auxico Resources Canada Inc. | President, Auxico Resources Canada Inc. |
pg@auxicoresources.com | mb@auxicoresources.com |
Cell: +1 514 299 0881 | Cell: +1 514 296 1641 |
About Auxico Resources Canada Inc.
Auxico Resources Canada Inc. (“Auxico”) is a Canadian company that was founded in 2014 and based in Montreal. Auxico is engaged in the acquisition, exploration and development of mineral properties in Colombia and Mexico.
The Canadian Securities Exchange (CSE) has not reviewed and does not accept responsibility for the adequacy or the accuracy of the contents of this release.
- Published in Auxico Resources
DIAGNOS Installs its First Retina Screening Clinic based on Artificial Intelligence in Panama
Momentum Public Relations
Press Release: July 10 2018
Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX VENTURE:ADK), (OTCQB:DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence (AI), announces today the installation of its first retina AI screening clinic, in the Panama’s private health sector.
“We are delighted to open our first of 15 Medical clinics in Panama in collaboration with DIAGNOS,” said the CEO and owner of these clinics. He also added: “We encourage and support DIAGNOS in its endeavor as an AI pioneer in the early detection of critical health issues, such as diabetic retinopathy. We are also looking forward to the upcoming release of the hypertension application.”
“We are looking forward to a long term relationship with our new customer in Panama. We have been working with their team to establish a marketing strategy to support their growth objectives. We are anticipating a substantial growth in the number of patients to screen,” said Guillermo Moreno, Vice-President at DIAGNOS.
About DIAGNOS
DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (“POC”). CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time and has been cleared for commercialization by several regulatory authorities such as Health Canada, the U.S. Food and Drug Administration and the European Union.
Additional information about DIAGNOS is available at www.diagnos.com and www.sedar.com.
For further information, please contact:
André Larente, President | Josh Falle | ||
DIAGNOS Inc. | Momentum PR | ||
Tél. : 450 678-8882, poste 224 | Tel: 514-416-4656 | ||
alarente@diagnos.ca | josh@momentumpr.com |
This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- Published in Diagnos
DIAGNOS Broadens its Collaboration with the Government of Mexico
Momentum Public Relations
Press Release: July 4 2018
Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX-V:ADK), (OTCQB:DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence (AI), announces today an expansion of its screening services with the Mexican government in one northern state of Mexico. As per the agreement, DIAGNOS plans to screen 10,000 patients by December 31, 2018.
“In Mexico, a large portion of our government’s budget and expenses is going towards the medical treatment of two major problems for our patients’ health; diabetes and hypertension. Our objective is to collaborate with DIAGNOS in order to provide a preventive and a better way of monitoring our patients health”, said the Chief Medical Officer of the state. The Chief Medical Officer of the state also added: “We strongly believe that this preventive approach will strongly benefit our patients and generate substantial savings in future healthcare costs”.
The project consists of the screening of 10,000 patients by December 31, 2018, with a vision to extend the project for the following years. “We have been working with the diabetes team at the state level, and are able to provide the right solution at the right time”, said Guillermo Moreno, Vice-President at DIAGNOS.
About DIAGNOS
DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (“POC”). CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time and has been cleared for commercialization by several regulatory authorities such as Health Canada, the U.S. Food and Drug Administration and the European Union.
Additional information about DIAGNOS is available at www.diagnos.com and www.sedar.com.
For further information, please contact:
André Larente, President | Josh Falle | ||
DIAGNOS Inc. | Momentum PR | ||
Tél. : 450 678-8882, poste 224 | Tel: 514-416-4656 | ||
alarente@diagnos.ca | josh@momentumpr.com |
This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- Published in Diagnos